Related Experiment Video

Updated: Mar 16, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

893

Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia

Xiaomeng Huang1,2,3, Sebastian Schwind3, Ramasamy Santhanam3

  • 1Molecular Cellular and Developmental Biology, The Ohio State University, Columbus, OH, USA.

Oncotarget
|August 13, 2016
PubMed

Insights

MicroRNA-181a (miR-181a) targets the RAS pathway, inhibiting acute myeloid leukemia (AML) growth. Restoring miR-181a levels reduces AML proliferation and improves chemotherapy sensitivity, offering a new therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Nanomedicine

Background:

  • MicroRNA (miRNA) deregulation is common in acute myeloid leukemia (AML).
  • Low miR-181a expression correlates with poor AML prognosis, but its mechanism is unclear.
  • RAS pathway activation is a key driver in myeloid leukemogenesis.

Purpose of the Study:

  • To elucidate the mechanism by which miR-181a affects AML growth.
  • To investigate the therapeutic potential of miR-181a restoration in AML.
  • To evaluate nanoparticle-mediated delivery of miR-181a mimics.

Main Methods:

  • Investigated miR-181a binding to KRAS, NRAS, and MAPK1 3'-UTRs.
  • Utilized transferrin-targeted lipopolyplex nanoparticles (NP) for miR-181a mimic delivery.
  • Assessed AML cell proliferation, colony formation, chemotherapy sensitivity, and RAS effector phosphorylation.

Main Results:

  • miR-181a directly downregulates KRAS, NRAS, and MAPK1, inhibiting AML growth.
  • Nanoparticle delivery of miR-181a mimics reduced AML proliferation and chemotherapy resistance.
  • Restoration of miR-181a function was validated by ectopic expression of its targets.
  • Treatment with miR-181a-loaded nanoparticles prolonged survival in a murine AML model.

Conclusions:

  • miR-181a targets the RAS-MAPK pathway, demonstrating anti-leukemic activity in AML.
  • miR-181a mimics delivered via nanoparticles represent a promising therapeutic strategy for AML.
  • This approach may also be applicable to other RAS-driven cancers.
Keywords:
RASacute myeloid leukemiamiR-181amicroRNAnanoparticles

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K